Cargando…
Subtyping of sarcomas based on pathway enrichment scores in bulk and single cell transcriptomes
BACKGROUND: Sarcomas are highly heterogeneous in molecular, pathologic, and clinical features. However, a classification of sarcomas by integrating different types of pathways remains mostly unexplored. METHODS: We performed hierarchical clustering analysis of sarcomas based on the enrichment scores...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800234/ https://www.ncbi.nlm.nih.gov/pubmed/35093080 http://dx.doi.org/10.1186/s12967-022-03248-3 |
_version_ | 1784642215760363520 |
---|---|
author | Li, Shengwei Liu, Qian Zhou, Haiying Lu, Hui Wang, Xiaosheng |
author_facet | Li, Shengwei Liu, Qian Zhou, Haiying Lu, Hui Wang, Xiaosheng |
author_sort | Li, Shengwei |
collection | PubMed |
description | BACKGROUND: Sarcomas are highly heterogeneous in molecular, pathologic, and clinical features. However, a classification of sarcomas by integrating different types of pathways remains mostly unexplored. METHODS: We performed hierarchical clustering analysis of sarcomas based on the enrichment scores of 14 pathways involved in immune, stromal, DNA damage repair (DDR), and oncogenic signatures in three bulk tumor transcriptome datasets. RESULTS: Consistently in the three datasets, sarcomas were classified into three subtypes: Immune Class (Imm-C), Stromal Class (Str-C), and DDR Class (DDR-C). Imm-C had the strongest anti-tumor immune signatures and the lowest intratumor heterogeneity (ITH); Str-C showed the strongest stromal signatures, the highest genomic stability and global methylation levels, and the lowest proliferation potential; DDR-C had the highest DDR activity, expression of the cell cycle pathway, tumor purity, stemness scores, proliferation potential, and ITH, the most frequent TP53 mutations, and the worst survival. We further validated the stability and reliability of our classification method by analyzing a single cell RNA-Seq (scRNA-seq) dataset. Based on the expression levels of five genes in the pathways of T cell receptor signaling, cell cycle, mismatch repair, focal adhesion, and calcium signaling, we built a linear risk scoring model (ICMScore) for sarcomas. We demonstrated that ICMScore was an adverse prognostic factor for sarcomas and many other cancers. CONCLUSIONS: Our classification method provides novel insights into tumor biology and clinical implications for sarcomas. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03248-3. |
format | Online Article Text |
id | pubmed-8800234 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-88002342022-02-02 Subtyping of sarcomas based on pathway enrichment scores in bulk and single cell transcriptomes Li, Shengwei Liu, Qian Zhou, Haiying Lu, Hui Wang, Xiaosheng J Transl Med Research BACKGROUND: Sarcomas are highly heterogeneous in molecular, pathologic, and clinical features. However, a classification of sarcomas by integrating different types of pathways remains mostly unexplored. METHODS: We performed hierarchical clustering analysis of sarcomas based on the enrichment scores of 14 pathways involved in immune, stromal, DNA damage repair (DDR), and oncogenic signatures in three bulk tumor transcriptome datasets. RESULTS: Consistently in the three datasets, sarcomas were classified into three subtypes: Immune Class (Imm-C), Stromal Class (Str-C), and DDR Class (DDR-C). Imm-C had the strongest anti-tumor immune signatures and the lowest intratumor heterogeneity (ITH); Str-C showed the strongest stromal signatures, the highest genomic stability and global methylation levels, and the lowest proliferation potential; DDR-C had the highest DDR activity, expression of the cell cycle pathway, tumor purity, stemness scores, proliferation potential, and ITH, the most frequent TP53 mutations, and the worst survival. We further validated the stability and reliability of our classification method by analyzing a single cell RNA-Seq (scRNA-seq) dataset. Based on the expression levels of five genes in the pathways of T cell receptor signaling, cell cycle, mismatch repair, focal adhesion, and calcium signaling, we built a linear risk scoring model (ICMScore) for sarcomas. We demonstrated that ICMScore was an adverse prognostic factor for sarcomas and many other cancers. CONCLUSIONS: Our classification method provides novel insights into tumor biology and clinical implications for sarcomas. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03248-3. BioMed Central 2022-01-29 /pmc/articles/PMC8800234/ /pubmed/35093080 http://dx.doi.org/10.1186/s12967-022-03248-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Li, Shengwei Liu, Qian Zhou, Haiying Lu, Hui Wang, Xiaosheng Subtyping of sarcomas based on pathway enrichment scores in bulk and single cell transcriptomes |
title | Subtyping of sarcomas based on pathway enrichment scores in bulk and single cell transcriptomes |
title_full | Subtyping of sarcomas based on pathway enrichment scores in bulk and single cell transcriptomes |
title_fullStr | Subtyping of sarcomas based on pathway enrichment scores in bulk and single cell transcriptomes |
title_full_unstemmed | Subtyping of sarcomas based on pathway enrichment scores in bulk and single cell transcriptomes |
title_short | Subtyping of sarcomas based on pathway enrichment scores in bulk and single cell transcriptomes |
title_sort | subtyping of sarcomas based on pathway enrichment scores in bulk and single cell transcriptomes |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800234/ https://www.ncbi.nlm.nih.gov/pubmed/35093080 http://dx.doi.org/10.1186/s12967-022-03248-3 |
work_keys_str_mv | AT lishengwei subtypingofsarcomasbasedonpathwayenrichmentscoresinbulkandsinglecelltranscriptomes AT liuqian subtypingofsarcomasbasedonpathwayenrichmentscoresinbulkandsinglecelltranscriptomes AT zhouhaiying subtypingofsarcomasbasedonpathwayenrichmentscoresinbulkandsinglecelltranscriptomes AT luhui subtypingofsarcomasbasedonpathwayenrichmentscoresinbulkandsinglecelltranscriptomes AT wangxiaosheng subtypingofsarcomasbasedonpathwayenrichmentscoresinbulkandsinglecelltranscriptomes |